XRTX
Income statement / Annual
Last year (2024), XORTX Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, XORTX Therapeutics Inc.'s net income was -$4.76 M.
See XORTX Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2014
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$142.26 K
|
$55.53 K
|
$14.14 K
|
$16.04 K
|
$15.35 K
|
$19.32 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$142.26 K
|
-$55.53 K
|
-$14.14 K
|
-$16.04 K
|
-$15.35 K
|
-$19.32 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$264.29 K
|
$2.46 M
|
$6.50 M
|
$674.48 K
|
$217.78 K
|
$30.77 K
|
$342.25 K
|
$66.37 K
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$1.59 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$795.65 K
|
$380.92 K
|
$389.32 K
|
$36.92 K
|
| Selling & Marketing Expenses |
$1.74 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.33 M
|
$3.55 M
|
$3.32 M
|
$2.20 M
|
$861.93 K
|
$390.34 K
|
$795.65 K
|
$380.92 K
|
$389.32 K
|
$36.92 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.64 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$3.59 M
|
$6.01 M
|
$9.82 M
|
$2.87 M
|
$1.08 M
|
$421.10 K
|
$1.16 M
|
$464.07 K
|
$405.34 K
|
$36.92 K
|
| Cost And Expenses |
$3.59 M
|
$6.16 M
|
$9.87 M
|
$2.89 M
|
$1.10 M
|
$436.45 K
|
$1.16 M
|
$464.07 K
|
$405.34 K
|
$36.92 K
|
| Interest Income |
$175.27 K
|
$257.65 K
|
$101.37 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$4.39 K
|
$13.51 K
|
$37.21 K
|
$22.30 K
|
$15.46 K
|
$8.63 K
|
$0.00
|
| Depreciation & Amortization |
$55.71 K
|
$142.26 K
|
$55.53 K
|
$14.14 K
|
$16.04 K
|
$15.35 K
|
$19.32 K
|
$16.78 K
|
$16.02 K
|
$0.00
|
| EBITDA |
-$3.71 M |
-$2.06 M |
-$6.94 M |
-$1.29 M |
-$981.67 K |
-$441.46 K |
-$1.07 M |
-$427.11 K |
-$389.32 K |
-$36.92 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.17 M
|
$3.96 M
|
$2.88 M
|
$1.58 M
|
$87.43 K
|
-$49.05 K
|
-$2.71 M
|
-$47.09 K
|
-$25.52 K
|
$0.00
|
| Income Before Tax |
-$4.76 M
|
-$2.20 M
|
-$7.00 M
|
-$1.31 M
|
-$1.01 M
|
-$485.50 K
|
-$3.78 M
|
-$474.20 K
|
-$414.83 K
|
-$36.92 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$22.30 K
|
$10.09 K
|
$8.63 K
|
$0.00
|
| Net Income |
-$4.76 M
|
-$2.20 M
|
-$7.00 M
|
-$1.31 M
|
-$1.01 M
|
-$485.50 K
|
-$3.78 M
|
-$474.20 K
|
-$414.83 K
|
-$36.92 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.65 |
-1.08 |
-4.72 |
-1.19 |
-1.73 |
-1.06 |
-6.45 |
-2.24 |
-2.05 |
-0.49 |
| EPS Diluted |
-1.65 |
-1.08 |
-4.72 |
-1.19 |
-1.73 |
-1.06 |
-6.45 |
-2.24 |
-2.05 |
-0.49 |
| Weighted Average Shares Out |
$2.88 M
|
$1.98 M
|
$1.48 M
|
$1.09 M
|
$740.45 K
|
$595.49 K
|
$584.99 K
|
$211.45 K
|
$202.74 K
|
$75.57 K
|
| Weighted Average Shares Out Diluted |
$2.88 M
|
$1.98 M
|
$1.48 M
|
$1.09 M
|
$740.45 K
|
$595.49 K
|
$584.99 K
|
$211.45 K
|
$202.74 K
|
$75.57 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
